Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Public ClinicalTrials.gov record NCT00660387. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments With Parkinson Medicinal Products Who Continue to Experience Persistent Motor Fluctuations
Study identification
- NCT ID
- NCT00660387
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 35 participants
Conditions and interventions
Conditions
Interventions
- Levodopa carbidopa intestinal gel (LCIG) Drug
- Placebo Gel Drug
- Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets Drug
- Placebo (PBO) oral capsules Drug
- CADD-Legacy® 1400 ambulatory infusion pump Device
- PEG tube Device
- J-tube Device
Drug · Device
Eligibility (public fields only)
- Age range
- 30 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2009
- Primary completion
- Sep 30, 2011
- Completion
- Sep 30, 2011
- Last update posted
- Jan 15, 2015
2009 – 2011
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 45931 | Birmingham | Alabama | 35222 | — |
| Site Reference ID/Investigator# 45910 | Fountain Valley | California | 92708 | — |
| Site Reference ID/Investigator# 45925 | Oceanside | California | 92056 | — |
| Site Reference ID/Investigator# 45912 | Port Charlotte | Florida | 33890 | — |
| Site Reference ID/Investigator# 45935 | Chicago | Illinois | 60611 | — |
| Site Reference ID/Investigator# 45930 | Lexington | Kentucky | 40536 | — |
| Site Reference ID/Investigator# 45934 | New York | New York | 10032 | — |
| Site Reference ID/Investigator# 45929 | Winston-Salem | North Carolina | 27157 | — |
| Site Reference ID/Investigator# 45908 | Cincinnati | Ohio | 45267 | — |
| Site Reference ID/Investigator# 45922 | Cleveland | Ohio | 44195-0001 | — |
| Site Reference ID/Investigator# 45915 | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00660387, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 15, 2015 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00660387 live on ClinicalTrials.gov.